Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC at ASCO 2021

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)

CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC

ASCO 2021: Lung roundup

FGFR as a tumour agnostic indicator and its importance in the diagnosis and treatment of multiple solid tumour types

ASCO 2021: Precision and molecular reporting for prostate cancer

Neo-AEGIS: Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy

COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer

Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients

COVID-19 and cancer: Highlights from ASCO 2021

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer

JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care (BSC) versus BSC alone for advanced UC

Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia

Breast cancer roundup from ASCO 2021

OncoAlert and ecancer ASCO roundup - Day 4 and 5

ADT plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed mHSPC

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer

Marizomib in combination with temozolomide-based radiochemotherapy for newly diagnosed glioblastoma

Pembrolizumab improves on chemo in MSI-H/dMMR mCRC

Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC

PROMISE-GIM6: GnRH agonist use during chemotherapy for early breast cancer to preserve ovarian function

ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve CLL - Four-year follow up

IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLC

Clinically sufficient vitamin D levels at breast cancer diagnosis and survival outcomes

Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in mCC

Adjuvant chemo following chemoradiation as treatment for locally advanced cervical cancer compared to chemoradiation alone

Tislelizumab in oesophageal cancer after systemic therapy

HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in MIBC patients

CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC

PEACE-1: Abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo mCSPC

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor

Highlights from ASCO 2021

OncoAlert and ecancer ASCO roundup - Day 3

PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC

OncoAlert and ecancer ASCO roundup - Day 2

OncoAlert and ecancer ASCO roundup - Day 1

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC

Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma

Clinical trials participation is directly influenced by the information received by cancer patients and caregivers

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC

Incidence and trends of HPV-related cancers in the United States

ASCO 2021: Latest on PARPi and other treatments for mCRPC

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma

Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advanced ESCC

ASCO 2021: Renal cancer roundup

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma